International Myeloma Working Group

Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

By imwg On September 28, 2015 · Add Comment · In IMWG Publications, Transplant

In contrast to the upfront setting in which the role of high-dose therapy with autologous hematopoietic cell transplantation (HCT) as consolidation of a first remission in patients with multiple myeloma (MM) is well established, the role of high-dose therapy with autologous or allogeneic HCT has not been extensively studied in MM patients relapsing after primary therapy. The International Myeloma Working Group together with the Blood and Marrow Transplant Clinical Trials Network, the American Society of Blood and Marrow Transplantation, and the European Society of Blood and Marrow Transplantation convened a meeting of MM experts to: (1) summarize current knowledge regarding the role of autologous or allogeneic HCT in MM patients progressing after primary therapy, (2) propose guidelines for the use of salvage HCT in MM, (3) identify knowledge gaps, (4) propose a research agenda, and (5) develop a collaborative initiative to move the research agenda forward.

Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group

Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma

Categories

Search